| Market Capitalization (Millions $) |
360 |
| Shares
Outstanding (Millions) |
71 |
| Employees |
59 |
| Revenues (TTM) (Millions $) |
0 |
| Net Income (TTM) (Millions $) |
-95 |
| Cash Flow (TTM) (Millions $) |
-98 |
| Capital Exp. (TTM) (Millions $) |
0 |
Altimmune Inc
Altimmune Inc is a clinical-stage biopharmaceutical company that specializes in developing and commercializing therapies for the treatment of infectious diseases, immunological disorders, and liver diseases. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Altimmune uses a proprietary technology platform, called RespirVec, to develop its vaccines and immunotherapies. RespirVec is a respiratory virus-based vector system that enables the efficient delivery of antigens directly to the immune system, resulting in a robust immune response. The platform is highly versatile, with the ability to deliver a wide range of vaccine candidates and therapeutic proteins.
One of Altimmune's lead programs is the development of a single-dose, intranasal COVID-19 vaccine candidate, AdCOVID. This vaccine uses Altimmunees RespirVec technology to deliver the spike protein antigen of SARS-CoV-2, the virus that causes COVID-19. The company is currently conducting Phase 1 trials for AdCOVID, and is confident that the vaccine will be effective in preventing COVID-19, both in the initial pandemic and in future waves.
Altimmune has a robust pipeline of other infectious disease programs, including a hepB vaccine, a flu vaccine, and an anthrax vaccine. The company is also developing immunotherapies for chronic hepatitis B, Alpha-1 Antitrypsin Deficiency, and NASH (non-alcoholic steatohepatitis).
Altimmune maintains partnerships and collaborations with other leading biopharmaceutical companies, including the University of Alabama at Birmingham, the University of Maryland School of Medicine, and the University of North Carolina at Chapel Hill. These collaborations give Altimmune access to world-class research facilities, expertise, and resources.
Overall, Altimmune Inc is a cutting-edge biopharmaceutical company that is at the forefront of developing innovative therapies for some of the world's most pressing health issues. With its strong pipeline, proprietary technology platform, and collaborative approach, Altimmune is well-suited to continue making significant contributions to the field of biopharmaceuticals.
Company Address: 910 Clopper Road Gaithersburg 20878 MD
Company Phone Number: 654-1450 Stock Exchange / Ticker: NASDAQ ALT
|
9.33% 